

**Supplementary file 1.** Baseline characteristics of the 259 SSc patients performing the first 6MWT at baseline and 6-month visit characteristics of the 27 SSc patients performing the first 6MWT at 6-month visit.

Characteristic	First 6MWT at baseline		First 6MWT at 6-month visit		P
	N		N		
Age (years) °	259	51.54 ± 13.54	27	51.37 ± 16.03	0.950
♀/♂*	259	195/64 (75.3/24.7)	27	21/6 (77.8/22.2)	0.775
Raynaud*	259	255 (98.5)	27	26 (96.3)	0.416
Disease duration since first Raynaud (months)°	255	117.68 ± 138.73	26	137.27 ± 171.98	0.503
Disease duration since first non-Raynaud (months) °	229	70.59 ± 90.52	24	75.25 ± 75.26	0.808
LSSc/LcSSc/DcSSc*	259	68/151/40 (26.3/58.3/15.4)	27	3/16/8 (11.1/59.3/29.6)	0.024
ACA*	259	123 (47.5)	27	9 (33.3)	0.161
AntiScl70 AB*		46 (17.8)		5 (18.5)	0.922
mRSS #	259	4.0 (0.0-10.0)	27	10.0 (6.0-17.0)	0.001
DAS #	251	0.5 (0.5-2.0)	25	1.0 (0.5-2.0)	0.931
ILD limited/extended*	254	86/14 (33.9/5.5)	27	8/2 (29.6/7.4)	0.858
PAH*	245	7 (2.9)	25	0 (0)	0.392

°: mean ± SD, \*: n (%), #: median (IQR).

N: number of patients; SD: standard deviation; IQR: interquartile range; ♀: women; ♂: men; n: number; %: percent; Raynaud: presence of Raynaud's phenomenon, non-Raynaud: presence of first non-Raynaud's phenomenon; LSSc: limited systemic sclerosis; LcSSc: limited cutaneous systemic sclerosis; DcSSc: diffuse cutaneous systemic sclerosis; mRSS: modified Rodnan Skin Score; DAS: disease activity score; ACA: anti-centromere antibodies; AntiScl70 AB: anti-topoisomerase I antibodies; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension.